Open an account

Protagonist Therapeutics

PTGX · NASDAQ

$137.99+$3.55 (+2.64%)TodayMarket closed ·
Prev close $134.44

About PTGX

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 132 full-time employees. The company went IPO on 2016-08-11. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The firm also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

Employees
131
Headquarters
Newark California, California
Listed
Aug 11, 2016
Sector
Health Care
Industry
Biotechnology
Website
protagonist-inc.com

PTGX key statistics

Market cap
8.70B
Price-earnings ratio
131.80
Dividend yield
—
Average volume
817.02K
Volume
774.30K
Open price
$135.87
High today
$140.82
Low today
$134.33
52 Week high
$160.81
52 Week low
$73.08

Protagonist Therapeutics (PTGX) at a glance

Protagonist Therapeutics (PTGX) last traded at $137.99, with a market cap of 8.70B and a price-to-earnings ratio of 131.80.

Today the stock has traded between $134.33 and $140.82. The current price is 2.7% above the day's low and 2.0% below its high.

Volume so far is 774.30K shares, in line with the average of 817.02K shares a day.

Over the past year Protagonist Therapeutics has ranged from $73.08 to $160.81, and now sits 74% of the way up that range.

Protagonist Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $2.29 per share against an estimate of $2.12.

The average analyst price target is $179.13, 29.8% above the current price, from 15 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 15 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 16 analystsAvg $179.13
Low
$151.50
Now
$137.99
High
$236.25

PTGX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 95.1% on average.

  1. Q3 FY24: reported -$0.54 per share against an estimate of -$0.6197
  2. Q4 FY24: reported $1.98 per share against an estimate of $0.3275
  3. Q1 FY25: reported -$0.19 per share against an estimate of -$0.2357
  4. Q2 FY25: reported -$0.55 per share against an estimate of -$0.59
  5. Q3 FY25: reported -$0.62 per share against an estimate of -$0.6518
  6. Q4 FY25: reported -$0.69 per share against an estimate of -$0.4983
  7. Q1 FY26: reported $0.05 per share against an estimate of -$0.5435
  8. Q2 FY26: reported $2.29 per share against an estimate of $2.12

PTGX news

  • Press releasePRNewswire

    A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

  • Vandana Singh

    Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug

  • Vandana Singh

    Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug

  • Vandana Singh

    This $300 Million Biotech May Be Deeply Mispriced: Analyst

  • Vandana Singh

    AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition

  • Vandana Singh

    Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data

  • Press releaseBusiness Wire

    Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

  • Press releaseBusiness Wire

    Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

Similar companies

Companies in the same industry as Protagonist Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.